LATE CONSOLIDATIVE RADIATION-THERAPY IN THE TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER

被引:0
作者
CARLSON, RW
SIKIC, BI
GANDARA, DR
HENDRICKSON, CG
WITTLINGER, PS
SHIELDS, JA
WONG, PP
WHITE, JE
MEAKIN, CJ
MCWHIRTER, KM
LAMBORN, KR
PHILLIPS, TL
机构
[1] UNIV CALIF DAVIS,DIV HEMATOL ONCOL,DAVIS,CA 95616
[2] VET ADM MED CTR,MARTINEZ,CA 94553
[3] KAISER FDN HOSP,SAN FRANCISCO,CA
[4] SAN JOAQUIN VALLEY CCOP,FRESNO,CA
[5] NO NEVADA CANC COUNCIL,RENO,NV
[6] BAY AREA TUMOR INST CCOP,OAKLAND,CA
[7] GREATER CONTRA COSTA CTY CANC PROGRAM,WALNUT CREEK,GA
[8] STANFORD UNIV,DEPT RADIAT ONCOL,STANFORD,CA 94305
[9] NO CALIF CANC CTR,BELMONT,CA
[10] UNIV CALIF SAN FRANCISCO,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143
关键词
D O I
10.1002/1097-0142(19910901)68:5<948::AID-CNCR2820680507>3.0.CO;2-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two hundred twenty-three patients were enrolled on this randomized Phase III trial testing the value of late consolidative involved-field radiation therapy in the treatment of limited-stage small cell lung cancer (SCLC). Patients were treated with induction chemotherapy consisting of alternating cycles of procarbazine, vincristine, lomustine, and cyclophosphamide (POCC) and etoposide, doxorubicin, and methotrexate (VAM) for 6 to 9 months. Responding patients were then randomized at 6 or 9 months to chemotherapy alone or to involved-field radiation therapy. All partial and complete responders received prophylactic cranial irradiation. Of the 180 eligible and evaluable patients, 80 (44%) achieved a complete response and 39 (22%) achieved a partial response (overall rate of response, 66%). Actuarial median survival time was 11.6 months, with 16% of patients surviving 2 years and 11% surviving 5 years. Forty-eight patients were randomized to chemotherapy alone (24 patients) versus chemotherapy plus involved-field radiation therapy (24 patients). There were no significant differences in time to progression or survival between those patients receiving or not receiving involved-field radiation therapy. The thorax was the site of first relapse in 58% of patients randomized to chemotherapy alone versus 29% in patients randomized to chemotherapy plus involved-field radiation therapy (P equals 0.042). The major acute toxicity was reversible myelosuppression, and the major late toxicity was chronic central nervous system dysfunction. The authors conclude that the addition of late consolidative radiation therapy to induction chemotherapy in the treatment of limited-stage SCLC is well tolerated and improves local control, but does not improve time to progression or rates of survival.
引用
收藏
页码:948 / 958
页数:11
相关论文
共 27 条
[1]   ALTERNATING RADIOTHERAPY AND CHEMOTHERAPY SCHEDULES IN SMALL CELL LUNG-CANCER, LIMITED DISEASE [J].
ARRIAGADA, R ;
LECHEVALIER, T ;
BALDEYROU, P ;
PICO, JL ;
RUFFIE, P ;
MARTIN, M ;
ELBAKRY, HM ;
DUROUX, P ;
BIGNON, J ;
LENFANT, B ;
HAYAT, M ;
ROUESSE, JG ;
SANCHOGARNIER, H ;
TUBIANA, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1985, 11 (08) :1461-1467
[2]   CHEMOTHERAPY ALONE OR CHEMOTHERAPY WITH CHEST RADIATION-THERAPY IN LIMITED STAGE SMALL-CELL LUNG-CANCER - A PROSPECTIVE, RANDOMIZED TRIAL [J].
BUNN, PA ;
LICHTER, AS ;
MAKUCH, RW ;
COHEN, MH ;
VEACH, SR ;
MATTHEWS, MJ ;
ANDERSON, AJ ;
EDISON, M ;
GLATSTEIN, E ;
MINNA, JD ;
IHDE, DC .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (05) :655-662
[3]  
BYHARDT RW, 1983, CANCER TREAT REP, V67, P209
[4]  
CHAK LY, 1982, CANCER, V50, P1857, DOI 10.1002/1097-0142(19821101)50:9<1857::AID-CNCR2820500933>3.0.CO
[5]  
2-I
[6]  
COHEN MH, 1983, CANCER TREAT REP, V67, P217
[7]  
Cox D.R., 1989, ANAL BINARY DATA, V32
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   THE EFFECT OF DOSE OF THORACIC IRRADIATION ON RECURRENCE IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG-CANCER - INITIAL RESULTS OF A CANADIAN MULTICENTER RANDOMIZED TRIAL [J].
COY, P ;
HODSON, I ;
PAYNE, DG ;
EVANS, WK ;
FELD, R ;
MACDONALD, AS ;
OSOBA, D ;
PATER, JL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 14 (02) :219-226
[10]   CHEMOTHERAPY OF SMALL-CELL CARCINOMA OF LUNG - A RANDOMIZED COMPARISON OF ALTERNATING AND SEQUENTIAL COMBINATION CHEMOTHERAPY PROGRAMS [J].
DANIELS, JR ;
CHAK, LY ;
SIKIC, BI ;
LOCKBAUM, P ;
KOHLER, M ;
CARTER, SK ;
REYNOLDS, R ;
BOHNEN, R ;
GANDARA, D ;
YU, J .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1192-1199